children with thromboembolism (U. Nowak-Göttl, H. Weiler, personal communication, July 2009), 1 and also with results from adult patients with deep venous thrombosis. 4 One explanation for the discrepancy may be the timing of blood collection. In our studies, blood was collected in the acute phase of the diseases. We observed a significant correlation between ␥Ј ratios and CRP levels in the acute phase (Rs ϭ 0.23, P Ͻ .001) in the patients with IS. 2 Moreover, ␥Ј ratios were slightly higher (0.24 Ϯ 0.19, n ϭ 16) in PE patients with CRP levels Ͼ 100 mg/L, than in patients who did not have an acute phase response (CRP levels Յ 10 mg/L; 0.20 Ϯ 0.06, n ϭ 13, P ϭ .54). These results together support our hypothesis that the mRNA processing of the fibrinogen ␥ alters during an acute phase reaction.The characteristics of ␥Ј-fibrinogen suggest that a high ratio during the acute phase of disease prevents thrombotic events in patients with UAP. In our patient group, there was no difference in ratios between stabilized (n ϭ 130) and refractory (n ϭ 72) patients (both 0.14 Ϯ 0.04, P ϭ .59). Neither were the ratios associated with clinical outcome during 18 months of follow-up. These results suggest that elevated ratio does not predict the risk of acute coronary syndromes in patients with UAP.In conclusion, the fibrinogen ␥Ј/total fibrinogen ratios are elevated in patients with various cardiovascular diseases (IS, PE, or UAP) compared with the ␥Ј ratios in healthy controls. An altered mRNA processing of fibrinogen ␥ during the acute phase may contribute to this observation. However, the fibrinogen ␥Ј/total fibrinogen ratio does not predict short-or long-term outcome in patients with UAP.